1085 / 1851
Turrisi AT et al NEJM 1999;340
3) Altered fractionation - Intergroup trial 0096:
the current standard in LD-SCLC?
Overall Survival
417 Patients
All patients received 4 x Cis+Etoposide
Randomly assigned to receive either
45 Gy twice daily (1.5 Gy/bid) or once
daily (1.8 Gy/die)
Higher rates of G3+ esophageal
toxicity in the accelerated arm
10% gain in OS @ 5 year:
26% vs 16%
p = 0.04
The schedules were not biologically equivalent!